The main research interest of the Integrative Genomics Lab revolves around the genetic basis of disease in humans. We identify emerging questions into complex disease etiology and tackle them using an integrative approach at the interface of statistical, quantitative and evolutionary genomics. Through collaboration with doctors working in the clinic, we analyze omic profiles of patient cohorts to illuminate our understanding of disease pathogenesis and, eventually, gear this knowledge towards translational advances. Our high vision focuses on achieving precision medicine: being able to use individual profiles to personalize health treatment and tailor medical care to patient needs.
Research line 1: Coupling statistical genetics with multi-omics to understand disease
We want to characterize the genetic regulatory programs that modulate risk of disease. We capitalize on two developments. First, large-scale genomic studies have discovered thousands of genetic variants that increase susceptibility to disease. Second, high-throughput methodologies can now generate multi-omic profiles to characterize the activity of cells and tissues in each person. Through integrative approaches, we can understand how genetic risk and lifestyle factors converge at the molecular level to shape the risk of developing disease. We pay special attention to discovering compensatory responses that may explain the heterogeneity in symptoms that we see at the clinical level. We focus on inflammatory and metabolic disease, but we are happy to collaborate with researchers working on other disease classes.
Research line 2: Individualization of predictions across the natural history of disease
A central goal of precision medicine is to deliver numerical scores that can assess the risk of disease and predict response to drug therapy for everyone. Building from an omics personality perspective, we posit that longitudinal profiling of each person will be key to implement precision medicine approaches. We integrative genomic knowledge with insights from other omics like transcriptomics, proteomics, and metabolomics, to stratify the population and develop integrative models that permit to characterize the disease trajectory of each patient across time.
Research line 3: Multi-omics of preclinical disease to propose preventive strategies
Modern medicine is reactive: it focuses on management of patients that are diagnosed after symptoms are established. This static vision considers diseases as chronic and incurable. This approximation trickles down into basic research. Rather than targeting the root causes that modify disease course, most studies focus on comparisons of patients and healthy controls. We are particularly interested in characterizing the preclinical stages of disease. Our goal is to discover gene signatures that are active in the transition from healthiness to disease. We posit that uncovering the genetic and environmental factors that influence these signatures maximizes the chances to discover biomarkers that can be used for prevention of chronic disease. The EARLY study for preclinical inflammatory bowel disease is our flagship initiative in this area.
In summary, our research strengthens the genomics and bioinformatics research portfolio at the CIC bioGUNE. We provide an integrative –omics perspective aimed at helping towards successful implementation of precision medicine solutions in the Basque Country. If you are interested in our work, or are considering joining the lab (at any level), please contact us at umartinez@cicbiogune.es
Collaborations
We have established a portfolio of collaborations with experts in disparate fields, including both basic and clinical researchers at the Basque, Spanish, and international level. Our active collaborations with clinicians include, among others, Iago Rodriguez-Lago (Hospital de Galdakao, Spain), Luis Bujanda (BioGipuzkoa, Spain), Maria Chaparro and Javier Gisbert (Hospital La Princesa, Spain) and Polychronis Pavlidis (King’s College London). Focusing on more basic profiles, we work closely with Oscar Lao (Barcelona, IBE-UPF/CSIC, artificial intelligence for genomics, Spain), Jorge Ferrer (Barcelona, CRG, Diabetes genomics in the context of IMPaCT T2D, Spain) and Eduard Porta-Pardo (Barcelona, JCLRI, spatial omics, Spain).
Links
Webpage: https://sites.google.com/view/integrative-genomics/home
-
Group Leader
Urko Martínez Marigorta
Ikerbasque Research Fellow - Ramón y Cajal (RyC) Programme POSTDOCTORAL RESEARCHER -
Nuria Rivera Brugues
-
Meriç Erdolu
-
Dimitrios Kioroglou
TECHNICIANS / DOCTORAL CANDIDATES -
Álvaro Raya Marín
-
Juan Antonio Miguel Gonzalez
-
Beatriz Mateos Andrés
Members
Latest Publications
A comprehensive phylogeny of mammalian PRNP gene reveals no influence of prion misfolding propensity on the evolution of this gene
Sampedro-Torres-Quevedo, C; Eraña, H; Charco, JM; Díaz-Domínguez, CM; San-Juan-Ansoleaga, M; Fernández-Muñoz, E; Gonçalves-Anjo, N; Galarza-Ahumada, J; Cortazar, AR; Nespolo, RF; Quintero-Galvis, ...
PLOS PATHOGENS
2025-06-01
Single-cell analysis reveals significant transcriptomic alterations in preclinical Crohn's disease
Kioroglou, D; Egia-Mendikute, L; Palazon, A; Acosta, MBD; Rodríguez-Lago, I; Marigorta, UM;
FRONTIERS IN IMMUNOLOGY
2025-05-22
Multi-omic integration sets the path for early prevention strategies on healthy individuals
Kioroglou, D; Gil-Redondo, R; Embade, N; Bizkarguenaga, M; Conde, R; Millet, O; Mato, JM; Marigorta, UM;
NPJ GENOMIC MEDICINE
2025-05-03
Precision proteogenomics reveals pan-cancer impact of germline variants
Rodrigues, FM; Terekhanova, NV; Imbach, KJ; Clauser, KR; Selvan, ME; Mendizabal, I; Geffen, Y; Akiyama, Y; Maynard, M; Yaron, TM; Li, YZ; Cao, S; Storrs, EP; Gonda, OS; Gaite-Reguero, A; Govindan, ...
CELL
2025-05-01
Characterization of the Regulatory Landscape in Crohn's Disease Reveals microRNA-Associated Alterations that Shape Anti-TNF Response
Cervera-Seco, L; Baldán-Martín, M; Fernández-Tomé, S; Moreno, LO; Lozano, JJ; Aransay, AM; Chaparro, M; Gisbert, JP; Marigorta, UM;
INFLAMMATORY BOWEL DISEASES
2025-03-11
Mitochondrial Dysfunction: Unraveling the Elusive Biology Behind Anti-TNF Response During Ulcerative Colitis
Kioroglou, D; Peña-Cearra, A; Corraliza, AM; Seoane, I; Castelo, J; Panés, J; Gómez-Irwin, L; Rodríguez-Lago, I; de Zarate, JO; Fuertes, M; Martín-Ruiz, I; Gonzalez, M; Aransay, AM; Salas, A; ...
INFLAMMATORY BOWEL DISEASES
2025-02-13
Natural history, immunological and genetic characteristics of preclinical inflammatory bowel disease (EARLY): study protocol for a prospective cohort study
Rodríguez-Lago, I; Marigorta, UM; Mateos, B; Mañosa, M; Márquez-Mosquera, L; Menchén, L; Rodríguez-Moranta, F; Alonso, I; Aguas, M; Alonso-Galán, H; Borràs, P; Castro, B; Domenech, E; Ferreiro-Iglesias, ...
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
2025-01-01
Seroprevalence of adeno-associated virus types 1, 2, 3, 4, 5, 6, 8, and 9 in a Basque cohort of healthy donors
Navarro-Oliveros, M; Vidaurrazaga, A; Guerra, GS; Castellana, D; Embade, N; Millet, O; Marigorta, UM; Abrescia, NGA;
SCIENTIFIC REPORTS
2024-07-10
Dysfunctional VLDL metabolism in MASLD.
Marigorta, Urko M; Millet, Oscar; Lu, Shelly C; Mato, Jose M;
NPJ metabolic health and disease
2024-01-01
Recent Advances and Potential Multi-Omics Approaches in the Early Phases of Inflammatory Bowel Disease
Rodríguez-Lago, I; Blackwell, J; Mateos, B; Marigorta, UM; Barreiro-de Acosta, M; Pollok, R;
JOURNAL OF CLINICAL MEDICINE
2023-05-11
microRNA-based signatures obtained from endometrial fluid identify implantative endometrium
Ibañez-Perez, J; Diaz-Nuñez, M; Clos-García, M; Lainz, L; Iglesias, M; Díez-Zapirain, M; Rabanal, A; Bárcena, L; González, M; Lozano, JJ; Marigorta, UM; González, E; Royo, F; Aransay, AM; Subiran, ...
HUMAN REPRODUCTION
2022-08-27
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
Martínez-Arranz, I; Bruzzone, C; Noureddin, M; Gil-Redondo, R; Mincholé, I; Bizkarguenaga, M; Arretxe, E; Iruarrizaga-Lejarreta, M; Fernández-Ramos, D; Lopitz-Otsoa, F; Mayo, R; Embade, N; Newberry, ...
HEPATOLOGY
2022-03-17
Local genetic variation of inflammatory bowel disease in Basque population and its effect in risk prediction
Garcia-Etxebarria, K; Merino, O; Gaite-Reguero, A; Rodrigues, PM; Herrarte, A; Etxart, A; Ellinghaus, D; Alonso-Galan, H; Franke, A; Marigorta, UM; Bujanda, L; DAmato, M;
SCIENTIFIC REPORTS
2022-03-01
METABOLIC SUBTYPES OF NONALCOHOLIC FATTY LIVER DISEASE PATIENTS EXHIBIT DISTINCTIVE CARDIOVASCULAR RISK PROFILES
Martínez-Arranz, I; Bruzzone, C; Noureddin, M; Gil-Redondo, R; Arretxe, E; Iruarrizaga-Lejarreta, M; Bizkarguenaga, M; Mincholé, I; Ramos, DF; Lopitz-Otsoa, F; Mayo, R; Embade, N; Newberry, ...
HEPATOLOGY
2021-10-01
Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression
Vosa, U; Claringbould, A; Westra, HJ; Bonder, MJ; Deelen, P; Zeng, B; Kirsten, H; Saha, A; Kreuzhuber, R; Yazar, S; Brugge, H; Oelen, R; de Vries, DH; van der Wijst, MGP; Kasela, S; Pervjakova, ...
NATURE GENETICS
2021-09-02
Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy
Verstockt, B; Noor, NM; Marigorta, UM; Pavlidis, P; Deepak, P; Ungaro, RC; Sci Workshop Steering Comm;
JOURNAL OF CROHNS & COLITIS
2021-03-17
Preclinical Inflammatory Bowel Disease: Back to the Future
Rodríguez-Lago, I; Marigorta, UM; Barreiro-de Acosta, M;
GASTROENTEROLOGY
2021-01-01
Reply to: Retesting the influences of mutation accumulation and antagonistic pleiotropy on human senescence and disease
Rodríguez, JA; Farré, X; Muntané, G; Marigorta, UM; Hughes, DA; Spataro, N; Bosch, E; Navarro, A;
NATURE ECOLOGY & EVOLUTION
2019-07-01
The Precision Medicine and Metabolism Laboratory is dedicated to advancing precision medicine through a detailed study of metabolism. Utilizing cutting-edge techniques such as NMR-based metabolomics, the laboratory analyzes extensive cohorts of urine and serum samples, enabling the examination of metabolic profiles across more than 10,000 individuals. This comprehensive approach aims to enhance the understanding of population-level metabolism and ultimately develop personalized medical treatments that are more effective and tailored to individual metabolic profiles.
In addition to its focus on precision medicine, the laboratory is deeply involved in investigating metabolism and liver diseases. The team employs advanced methods, including metabolomics and molecular biology, to unravel the molecular mechanisms underlying metabolic disorders and liver conditions, with the goal of identifying potential therapeutic strategies. Collaborating with local, national, and international institutions, the lab strives to drive innovation and scientific discovery, contributing to both the scientific community and public health by developing new diagnostic methods and advanced therapies. Our laboratory is currently exploring the following topics:
Research line 1: Metabolism
Metabolism describes the chemical reactions involved in maintaining the living state of the cells and the organism. In our laboratory, we are interested in the metabolic pathways that result in liver disease when ill-functioning and the biosynthetic pathway of the heme group. To that end, we use a combination of cellular, biochemical and biophysical techniques and, most specially, NMR spectroscopy. For instance, we have recently developed a methodology to describe the metabolism in a nutshell by using 31P-NMR spectroscopy.
Research line 2: Metabolomics
Metabolomics is the large-scale study of small molecules, commonly known as metabolites, within cells, biofluids, tissues or organisms. In our laboratory, we employ NMR-based metabolomics (methodology and applications) of urine and serum samples, targeting large cohorts (i. e. > 10.000 individuals). The final goal is to describe the population at the metabolic level and advance towards a precision medicine program within the region. To that end, we have a fully equipped laboratory including two IVDr 600 MHz spectrometers and a SamplePro robot.
Research line 3: Metabolomic rare diseases
Rare diseases (~7000 identified to date) are an area of significant medical need affecting an estimated 350 million people worldwide, with ~95% having no currently approved drug treatment. They are often produced by inherited mutations affecting the activity of a protein and it is becoming increasingly evident that, most frequently, a mutation destabilizes the protein/enzyme, ultimately affecting its intracellular homeostasis. In this context, pharmacological chaperones (small molecules which bind to the protein, restoring stability and activity without affecting its function) can be applied to many diseases. Inherited metabolic disorders represent a heterogeneous collection of genetic diseases caused by rare mutations that affect the function of individual proteins. In our laboratory we are interested in using NMR spectroscopy for the early detection of inborn errors of metabolism and to explore the mechanism and therapeutic intervention in two metabolic rare diseases: congenital erythropoietic porphyria, a disorder of the heme biosynthetic pathway and tyrosinemia type I, a disease related to the accumulation of tyrosine by-products. To that end, we make use of a plethora of techniques including CRISPR/Cas9, specific animal models and in-house designed NMR-based metabolic and fluxomic experiments.
Research line 4: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Our research emphasizes the use of metabolomics and lipidomics to identify biomarkers and develop non-invasive diagnostic tests for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The laboratory's work aims to understand the metabolic pathways and molecular mechanisms underlying liver diseases, which is critical for developing new therapeutic strategies and improving patient outcomes.
Research line 5: Protein stability
Protein stability (thermodynamic and kinetic) drives the biophysical properties of the polypeptide chain (protein folding) and the protein's concentration in the cellular environment (protein homeostasis). It is the result of a delicate balance between inter- and intramolecular interactions, which can be easily altered by mutations and/or upon changes in the composition of the surrounding media. In this context, NMR spectroscopy offers a plethora of suitable experiments to investigate protein stability.
Collaborations
Jeremy Nicholson & Julien Wist (Murdoch University). Ulrich Guenther (Lubeck University). Simon Mallal & Markus Voehler (Vanderbilt University). Gary Frost & Elaine Holmes (Imperial College). Manfred Spraul & Harmut Schaeffer (Bruker). Quentin Anstee (Newcastle University). Shelly Lu & Mazen Nouredin (Cedars Sinai). Quentin Anstee (Newcastle University). Toni Vidal (Cambridge University). Luca Valenti (University of Milan). Keneth Cusi (University of Florida). Nicholas Davidson (Washington University). Marco Arrese (Univ. Católica de Chile). Scott Friedman (Mount sinai). Arun Sanyal (Virginia University). Robert Desnick (Mount Sinai). Emmanuel Richard & Jean Marc Blouin (Université de Bordeaux). Dolores Corella (Universitat de Valencia). Eduardo Anguita (Hospital Clínico San Carlos). Juan Arriaga (Hospital de Basurto). Pedro España (Hospital de Galdakao). Miguel Ángel Morán (Hospital de Txagorritxu). Maria Luisa Seco (Osarten). Rubén Nogueiras & Miguel López (CIMUS). Beatriz Macías (Universidad de Extremadura). Jesús Bañales (Biodonostia). Antonio Martín-Duce (Hospital Príncipe de Asturias). Manuel Romero (Hospital Valme).
Links
https://www.omilletlab.com/
-
General Director
José M Mato
-
Gabriel Ortega Quintanilla
Ikerbasque Research Fellow - Ramón y Cajal (RyC) Programme RESEARCH ASSISTANT -
Nieves Embade
-
Fernando Lopitz Otsoa
SPECIALIST -
Beatriz González Valle
-
Rubén Gil Redondo
POSTDOCTORAL RESEARCHER -
Alain Ibañez de Opakua Lopez de Abetxuko
-
David Fernández Ramos
-
Andreas Schedlbauer
-
Mireia Pujals Pruneda
-
Daniel Jardón Álvarez
-
Riccardo Scarin
TECHNICIANS / DOCTORAL CANDIDATES -
Ángela de Diego Rodríguez
-
Pablo Herrero Alfonso
-
Virginia Gutiérrez de Juan
-
Margarita Gómez Galán
-
Maider Bizkarguenaga Uribiarte
-
Sara Martín Ramos
-
Sarah Kratzwald
-
Karen Salua Alarcón Morales
-
Idoia Iturrioz
-
Cristina Garrido
-
Laura Gálvez Larrosa
-
Lia Castro Espadas
-
Alba Pejenaute Pejenaute
Members
Óscar Millet
Latest Publications
S-adenosylmethionine deficit disrupts very low-density lipoprotein metabolism promoting liver lipid accumulation in mice
Luque-Urbano, MR; Fernández-Ramos, D; Lopitz-Otsoa, F; de Juan, VG; Bizkarguenaga, M; Castro-Espadas, L; Hermoso-Martínez, U; Barbier-Torres, L; Lu, SC; Millet, O; Mato, JM;
JOURNAL OF LIPID RESEARCH
2025-05-08
Multi-omic integration sets the path for early prevention strategies on healthy individuals
Kioroglou, D; Gil-Redondo, R; Embade, N; Bizkarguenaga, M; Conde, R; Millet, O; Mato, JM; Marigorta, UM;
NPJ GENOMIC MEDICINE
2025-05-03
Enhanced Standard Operating Procedures for 31P NMR-Based Metabolomics in Tissue Extracts
Martin-Ramos, S; Bilbao, J; Diercks, T; Mato, JM; Bernardo-Seisdedos, G; Millet, O;
JACS AU
2025-04-13
Fructose-induced progression of steatohepatitis involves disrupting aldolase B-AMPK signaling in methionine adenosyltransferase 1A deficient mice
Barbier-Torres, L; Luque-Urbano, M; Chhimwal, J; Robinson, AE; Fernández-Ramos, D; Lopitz-Otsoa, F; Van Eyk, JE; Millet, O; Mato, JM; Lu, SC;
METABOLISM-CLINICAL AND EXPERIMENTAL
2025-04-01
Management of drug-induced liver injury associated with anti-cancer therapy
Vincenzi, B; Yimin, M; Andrade, RJ; Castillo, MM; Akhundova-Unadkat, G; Mato, JM;
FRONTIERS IN PHYSIOLOGY
2025-03-27
S-Adenosylmethionine: A Multifaceted Regulator in Cancer Pathogenesis and Therapy
Fernández-Ramos, D; Lopitz-Otsoa, F; Lu, SC; Mato, JM;
CANCERS
2025-02-01
Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
Noureddin, M; Truong, E; Mayo, R; Martínez-Arranz, I; Mincholé, I; Banales, JM; Arrese, M; Cusi, K; Arias-Loste, MT; Bruha, R; Romero-Gómez, M; Iruzubieta, P; Aller, R; Ampuero, J; Calleja, ...
HEPATOLOGY
2025-01-01
Genetic algorithms applied to translational strategy in metabolic-dysfunction associated steatohepatitis (MASH). Learning from mouse models
Martínez-Arranz, I; Alonso, C; Mayo, R; Mincholé, I; Mato, JM; Lee, DJ;
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
2024-10-01
The role of forkhead box M1-methionine adenosyltransferase 2 A/2B axis in liver inflammation and fibrosis
Yang, B; Lu, LQ; Xiong, T; Fan, W; Wang, JH; Barbier-Torres, L; Chhimwal, J; Sinha, S; Tsuchiya, T; Mavila, N; Tomasi, ML; Cao, DY; Zhang, J; Peng, H; Mato, JM; Liu, T; Yang, X; Kalinichenko, ...
NATURE COMMUNICATIONS
2024-09-27
MetSCORE: a molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics
Gil-Redondo, R; Conde, R; Bruzzone, C; Seco, ML; Bizkarguenaga, M; González-Valle, B; de Diego, A; Lain, A; Habisch, H; Haudum, C; Verheyen, N; Obermayer-Pietsch, B; Margarita, S; Pelusi, S; ...
CARDIOVASCULAR DIABETOLOGY
2024-07-24
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
Vacca, M; Kamzolas, I; Harder, LM; Oakley, F; Trautwein, C; Hatting, M; Ross, T; Bernardo, B; Oldenburger, A; Hjuler, ST; Ksiazek, I; Lindén, D; Schuppan, D; Rodriguez-Cuenca, S; Tonini, MM; ...
NATURE METABOLISM
2024-06-01
Stratification of Sepsis Patients on Admission into the Intensive Care Unit According to Differential Plasma Metabolic Phenotypes
Lodge, S; Litton, E; Gray, N; Ryan, M; Millet, O; Fear, M; Raby, E; Currie, A; Wood, F; Holmes, E; Wist, J; Nicholson, JK;
JOURNAL OF PROTEOME RESEARCH
2024-03-21
Cross-Validation of Metabolic Phenotypes in SARS-CoV-2 Infected Subpopulations Using Targeted Liquid Chromatography-Mass Spectrometry (LC-MS)
Whiley, L; Lawler, NG; Zeng, AX; Lee, A; Chin, ST; Bizkarguenaga, M; Bruzzone, C; Embade, N; Wist, J; Holmes, E; Millet, O; Nicholson, JK; Gray, N;
JOURNAL OF PROTEOME RESEARCH
2024-03-14
Characterization of preovulatory follicular fluid secretome and its effects on equine oocytes during in vitro maturation
Luis-Calero, M; Marinaro, F; Fernández-Hernández, P; Ortiz-Rodríguez, JM; Casado, JG; Pericuesta, E; Gutiérrez-Adán, A; González, E; Azkargorta, M; Conde, R; Bizkarguenaga, M; Embade, N; Elortza, ...
RESEARCH IN VETERINARY SCIENCE
2024-03-11
Hepatic prohibitin 1 and methionine adenosyltransferase a1 defend against primary and secondary liver cancer metastasis
Fan, W; Cao, DY; Yang, B; Wang, JH; Li, XM; Kitka, D; Li, TWH; You, SY; Shiao, S; Gangi, A; Posadas, E; Di Vizio, D; Tomasi, ML; Seki, E; Mato, JM; Yang, HP; Lu, SC;
JOURNAL OF HEPATOLOGY
2024-03-01
Impaired Hepatic Very Low-Density Lipoprotein Secretion Promotes Tumorigenesis and Is Accelerated with Fabp1 Deletion
Newberry, EP; Molitor, EA; Liu, AL; Chong, KMY; Liu, XL; Alonso, C; Mato, JM; Davidson, NO;
AMERICAN JOURNAL OF PATHOLOGY
2024-02-28
Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naive Inflammatory Bowel Disease Patients
Aldars-García, L; Gil-Redondo, R; Embade, N; Riestra, S; Rivero, M; Gutiérrez, A; Rodríguez-Lago, I; Fernández-Salazar, L; Ceballos, D; Benitez, JM; Aguas, M; Baston-Rey, I; Bermejo, F; Casanova, ...
INFLAMMATORY BOWEL DISEASES
2024-02-01
Quantitative Analysis of the Human Semen Phosphorometabolome by 31P-NMR
Serrano, R; Martin-Hidalgo, D; Bilbao, J; Bernardo-Seisdedos, G; Millet, O; Garcia-Marin, LJ; Bragado, MJ;
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
2024-02-01
Effect of age and dietary habits on Red Blood Cell membrane fatty acids in a Southern Europe population (Basque Country)
Marrugat, G; Cano, A; Amézaga, J; Arranz, S; Embade, N; Millet, O; Ferreri, C; Tueros, I;
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
2024-01-01
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
Noureddin, M; Truong, E; Mayo, R; Martínez-Arranz, I; Banales, JM; Mincholé, I; Arrese, M; Cusi, K; Arias-Loste, MT; Bruha, R; Romero-Gómez, M; Iruzubieta, P; Aller, R; Ampuero, J; Calleja, ...
HEPATOLOGY
2024-01-01